Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 16;95(1):87.
doi: 10.1007/s00280-025-04810-8.

Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review

Saphal Lakshmi Pasupulati  1 , Katiboina Srinivasa Rao  2 , Sushil Sharma  3 , C Madhavrao  3 , Gaurav Rangari  3 , Arup Kumar Misra  3 , L V Simhachalam Kutikuppala  3 , T Devika  4 , Sandhya Rani Sarikonda  3
Affiliations
Review

Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review

Saphal Lakshmi Pasupulati et al. Cancer Chemother Pharmacol. .
No abstract available

Keywords: Cancer; Chemotherapy; PARP inhibitor; Talazoparib.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Informed consent: Not applicable. Consent to participate: Not applicable. Consent to publish: Not applicable.

References

    1. Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355(6330):1152–1158. https://doi.org/10.1126/science.aam7344 - DOI - PubMed - PMC
    1. George RR, Thomas R, Davice A, Mathew MS (2022) Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract 28(4):924–934. https://doi.org/10.1177/10781552221073990 - DOI - PubMed
    1. Pham MM, Hinchcliff E, Avila M, Westin SN The clinical challenges, trials, and errors of combatting Poly(ADP-Ribose) polymerase inhibitors resistance. Cancer J 2021 Nov-Dec 01;27(6):491–500. https://doi.org/10.1097/ppo.0000000000000562
    1. Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S (2019) Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 8:29. https://doi.org/10.1186/s40164-019-0154-9 - DOI - PubMed - PMC
    1. Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N et al (2022) Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27(3):167–174. https://doi.org/10.1093/oncolo/oyab053 - DOI - PubMed - PMC

LinkOut - more resources